Eddingpharm Raises $24 Million in Series B

Eddingpharm (Cayman) Inc., a Shanghai firm that seeks to in-license and then market Western drugs to hospitals in China, has closed a $24 million Series B financing. The company said it would use the new capital to in-license additional drugs, co-develop prescription drugs for sale in China, and seek M&A opportunities. More details....
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.